Total production -- Reached a quarterly record of approximately 1.62 million BOEs per day, reflecting a 19% increase, or ...

PN-943 (IBD Program) -- Oral, gut-restricted alpha-4-beta-7 integrin antagonist demonstrated greater than threefold improved ...

Net Income -- $7.6 million, down from $9.3 million. Net income attributable to Karat ( KRT +1.51%) was $7.3 million, or $0.36 ...

Acquisition Announcement -- VSE Corporation ( VSEC 0.75%) signed a definitive agreement to acquire Aero 3 for $350 million in ...

Q4 2025 guidance -- Projected total revenue of $371 million to $377 million; subscription revenue of $258 million to $261 ...

Relacorilant NDA updates -- FDA PDUFA date set for Dec. 30, 2025 (hypercortisolism); platinum-resistant ovarian cancer PDUFA ...

Recognition -- The company achieved a ranking of 74th in Time Magazine's America's Growth Leaders 2026 list, among over 4,000 ...

Join us as we dissect Lululemon's stock performance and explore whether it can reclaim its former glory in the competitive ...

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.

If you are looking to expand your investments in AI but want to diversify your portfolio away from chip stocks, I think one ...

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

GEO’s latest quarter shows a company pulling in record contracts while wrestling with litigation and cooling earnings ...